{"id": "1349480203010109448", "creation": 1610576127.0, "user_id": "937043107811659778", "social_network": "twitter", "nsfw": false, "request": ["b26b9dbc-1c5a-4cd3-a3a6-c2f5a51ad0fc"], "metrics": {"b26b9dbc-1c5a-4cd3-a3a6-c2f5a51ad0fc": {"retweet_count": 0, "reply_count": 1, "like_count": 2, "quote_count": 0}}, "quoted": "1349403395891884032", "text": "#JanssenCillag is part of @JNJNews, funding ENSAMBLE trial, phase 3a, 60 000 participants\n#COVID19 vaccine is non-replicant virus vector, using their AdVac &amp; PER.C6 systems, being used to develop company\u2019s #Ebola #vaccine\nPreprint publication, phase I/II https://t.co/RcNh0eLInM https://t.co/Y8qwrzAR8o", "first_save": 1634559108.199414, "hashtags": ["#JANSSENCILLAG", "#COVID19", "#EBOLA", "#VACCINE"]}